article thumbnail

New for 2022, California Estheticians Can Perform Brow Lamination, Lash Lifts & Tints!

California Skincare Supply

July, 2022 News Update FDA has approved lash and brow tinting for estheticians, and Refectocil has stepped up to the plate with their new product to meet the need. Read the actual bill here… But the FDA steps in with a warning in January 2022 That all sounds great, but there’s one problem. Estheticians can! That’s right.

article thumbnail

And Then There Were Six…FDA Green Lights Hugel’s Toxin for Glabellar Lines

The Dermatology Digest

.” Coral Gables, FL-based dermatologist Joely Kaufman, MD, adds, “The results from the clinical trials for letibotulinumtoxinA demonstrate efficacy, and a convincing safety profile in the treatment of glabellar lines. Hugel filed its first Biologics License Application in 2021, which was rejected by the FDA in 2022.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

If Fragrance In Skincare Scares You, Read This

Renee Rouleau

The bottom line is that synthetic fragrances are extremely pure and predictable since they’re made in a lab, so their safety is well understood. In December 2022, Congress passed the Modernization of Cosmetics Regulation Act (MoCRA). Up next, learn more about how your skincare products are tested to ensure safety.

Skincare 195
article thumbnail

Review Study Aims to Refine Safety Profile of JAK Inhibitors in AD

The Dermatology Digest

The comprehensive safety analysis establishes evidence regarding the safety of systematic Janus kinase inhibitors in patients with atopic dermatitis. They reviewed the available safety data and analyzed the risk of 11 adverse events from 14 RCTs published between 2019 and 2022.

Safety 36
article thumbnail

Review Study Aims to Refine Safety Profile of JAK Inhibitors in AD

The Dermatology Digest

They reviewed the available safety data and analyzed the risk of 11 adverse events from 14 RCTs published between 2019 and 2022. The post Review Study Aims to Refine Safety Profile of JAK Inhibitors in AD appeared first on The Dermatology Digest.

Safety 36
article thumbnail

Fenbendazole Joe Tippens Protocol: A Simple Step-by-Step Guide (2023)

Aesthetics Advisor

Since fenbendazole is a veterinary medicine, and is not licensed for human use and there is no specific human safety data available. The similar human forms of this class of medications, mebendazole and albendazole, have been used for parasitic infections for many years and have a good safety record. chemotherapy? His scan in Feb.

Therapy 69
article thumbnail

Oh, The Places Dermatology Will Go in 2024!

The Dermatology Digest

It has great efficacy and safety and is oral… [This means] no shot and no risk of anaphylaxis.” Upadacitinib’s (Rinvoq, AbbVie) 5-yr safety data show that it is REALLY SAFE and effective in AD, and abrocitinib (Cibinqo, Pfizer) is safe as well.” The BIG story is Janus kinase ( JAK ) inhibitors,” Dr. Martin says.